-- 3.2 Month Survival Benefit Demonstrated in Patients who had Already Received Prior Endocrine-based Therapy and at Least Two Prior Chemotherapies --
-- Trodelvy Now Shows a Survival Benefit in both Pre-treated HR+/HER2- Metastatic Breast Cancer and Second-Line Metastatic Triple-Negative Breast Cancer --
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the positive overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In the study, Trodelvy demonstrated a statistically significant and clinically meaningful improvement of 3.2 months in OS compared to TPC (median OS: 14.4 months vs. 11.2 months; hazard ratio [HR]=0.79; [95% confidence interval [CI]: 0.65-0.96]; p=0.02). OS was a key secondary endpoint of the trial.
These findings will be presented on Friday, September 9 at 4:20pm CEST during the European Society for Medical Oncology (ESMO) Congress 2022 as a late-breaking oral presentation (#LBA76) in the Brest Auditorium, Paris Expo Porte de Versailles.
Other key secondary endpoints including objective response rate (ORR) demonstrated statistically significant improvement in favoring Trodelvy versus TPC. Time to deterioration (TTD) of Global Health Status/Quality of Life (QoL) and Fatigue scale per EORTC-QLQ-C30 also favored Trodelvy versus TPC (QoL: 4.3 months vs. 3.0 months, p=0.006; Fatigue: 2.2 months vs. 1.4 months, p=0.002). No statistically significant difference in TTD on the Pain Scale was observed.
It is outstanding to see a clinically meaningful survival benefit of over three months for patients with pre-treated HR+/HER2- metastatic breast cancer, said Hope S. Rugo, MD, Professor of Medicine and Director, Breast Oncology and Clinical Trials Education at the University of California San Francisco Comprehensive Cancer Center, U.S. Nearly all patients with HR+/HER2- metastatic breast cancer will develop resistance to endocrine-based therapies even in combination with targeted agents, so these data are welcome news for the breast cancer community. The results of TROPiCS-02 highlight the potential for sacituzumab govitecan in patients with pre-treated HR+/HER2- metastatic breast cancer.
The safety profile for Trodelvy was consistent with prior studies, with no new safety signals identified in this patient population.
With these data from TROPiCS-02, Trodelvy has now demonstrated a survival benefit in both pre-treated HR+/HER2- metastatic breast cancer and second-line metastatic TNBC two difficult-to-treat forms of breast cancer, said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology. Our Gilead Oncology ambition is to transform care for people with cancer, and the meaningful improvement in survival benefit seen in the TROPiCS-02 study with Trodelvy is another step forward in pursuing this ambition for patients.
The TROPiCS-02 study met its primary endpoint of progression-free survival earlier this year; detailed results were presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Trodelvy has not been approved by any regulatory agency for the treatment of HR+/HER2- metastatic breast cancer. Its safety and efficacy have not been established for this indication. Gilead has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) based on data from TROPiCS-02; these data will also be shared with health authorities outside the U.S.
Sacituzumab govitecan-hziy is currently included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines)i. This includes a Category 1 recommendation for use in adult patients with second-line metastatic triple-negative breast cancer (defined as those who received at least two prior therapies, with at least one line for metastatic disease). It also has a Category 2A preferred recommendation for investigational use in HR+/HER2- advanced breast cancer after prior treatment including endocrine therapy, a CDK4/6 inhibitor and at least two lines of chemotherapy.
Trodelvy has a Boxed Warning for severe or life-threatening neutropenia and severe diarrhea; please see below for additional Important Safety Information.
About HR+/HER2- Breast Cancer
Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer is the most common type of breast cancer and accounts for approximately 70% of all new cases, or nearly 400,000 diagnoses worldwide each year. Almost one in three cases of early-stage breast cancer eventually become metastatic, and among patients with HR+/HER2- metastatic disease, the five-year relative survival rate is 30%. As patients with HR+/HER2- metastatic breast cancer become resistant to endocrine-based therapy, their primary treatment option is limited to single-agent chemotherapy. In this setting, it is common to receive multiple lines of chemotherapy regimens over the course of treatment, and the prognosis remains poor.
About the TROPiCS-02 Study
The TROPiCS-02 study is a global, multicenter, open-label, Phase 3 study, randomized 1:1 to evaluate Trodelvy versus physicians choice of chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine) in 543 patients with HR+/HER2- metastatic breast cancer who were previously treated with endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy for metastatic disease. The primary endpoint is progression-free survival per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by blinded independent central review (BICR) for participants treated with Trodelvy compared to those treated with chemotherapy. Secondary endpoints include overall survival, overall response rate, clinical benefit rate and duration of response, as well as assessment of safety and tolerability and quality of life measures. In the study, HER2 negativity was defined per American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) criteria as immunohistochemistry (IHC) score of 0, IHC 1+ or IHC 2+ with a negative in-situ hybridization (ISH) test. More information about TROPiCS-02 is available at https://clinicaltrials.gov/ct2/show/NCT03901339.
About Trodelvy
Trodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the microenvironment.
Trodelvy is approved in more than 35 countries, with multiple additional regulatory reviews underway worldwide, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Trodelvy is also approved in the U.S. under the accelerated approval pathway for the treatment of adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Trodelvy is also being developed for potential investigational use in other TNBC and metastatic UC populations, as well as a range of tumor types where Trop-2 is highly expressed, including hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, metastatic non-small cell lung cancer (NSCLC), metastatic small cell lung cancer (SCLC), head and neck cancer, and endometrial cancer.
U.S. Indications for Trodelvy
In the United States, Trodelvy is indicated for the treatment of:
U.S. Important Safety Information for Trodelvy
BOXED WARNING: NEUTROPENIA AND DIARRHEA
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
Neutropenia: Severe, life-threatening, or fatal neutropenia can occur and may require dose modification. Neutropenia occurred in 61% of patients treated with Trodelvy. Grade 3-4 neutropenia occurred in 47% of patients. Febrile neutropenia occurred in 7%. Withhold Trodelvy for absolute neutrophil count below 1500/mm3 on Day 1 of any cycle or neutrophil count below 1000/mm3 on Day 8 of any cycle. Withhold Trodelvy for neutropenic fever.
Diarrhea: Diarrhea occurred in 65% of all patients treated with Trodelvy. Grade 3-4 diarrhea occurred in 12% of patients. One patient had intestinal perforation following diarrhea. Neutropenic colitis occurred in 0.5% of patients. Withhold Trodelvy for Grade 3-4 diarrhea and resume when resolved to Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.
Hypersensitivity and Infusion-Related Reactions: Serious hypersensitivity reactions including life-threatening anaphylactic reactions have occurred with Trodelvy. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 37% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of Trodelvy was 0.3%. The incidence of anaphylactic reactions was 0.3%. Pre-infusion medication is recommended. Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Medication to treat such reactions, as well as emergency equipment, should be available for immediate use. Permanently discontinue Trodelvy for Grade 4 infusion-related reactions.
Nausea and Vomiting: Nausea occurred in 66% of all patients treated with Trodelvy and Grade 3 nausea occurred in 4% of these patients. Vomiting occurred in 39% of patients and Grade 3-4 vomiting occurred in 3% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold Trodelvy doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade 1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.
Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with Trodelvy. The incidence of Grade 3-4 neutropenia was 67% in patients homozygous for the UGT1A1*28, 46% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 25% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 11% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue Trodelvy based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.
Embryo-Fetal Toxicity: Based on its mechanism of action, Trodelvy can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. Trodelvy contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Trodelvy and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Trodelvy and for 3 months after the last dose.
ADVERSE REACTIONS
In the ASCENT study (IMMU-132-05), the most common adverse reactions (incidence 25%) were fatigue, neutropenia, diarrhea, nausea, alopecia, anemia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence 25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes.
In the TROPHY study (IMMU-132-06), the most common adverse reactions (incidence 25%) were diarrhea, fatigue, neutropenia, nausea, any infection, alopecia, anemia, decreased appetite, constipation, vomiting, abdominal pain, and rash. The most frequent serious adverse reactions (SAR) (5%) were infection (18%), neutropenia (12%, including febrile neutropenia in 10%), acute kidney injury (6%), urinary tract infection (6%), and sepsis or bacteremia (5%). SAR were reported in 44% of patients, and 10% discontinued due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence 25%) in the TROPHY study were reduced neutrophils, leukocytes, and lymphocytes.
DRUG INTERACTIONS
UGT1A1 Inhibitors: Concomitant administration of Trodelvy with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with Trodelvy.
UGT1A1 Inducers: Exposure to SN-38 may be substantially reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with Trodelvy.
Please see full Prescribing Information , including BOXED WARNING.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gileads ability to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials, including those involving Trodelvy; uncertainties relating to regulatory applications for Trodelvy and related filing and approval timelines, including with respect to the pending sBLA for Trodelvy, and pending or potential applications for the treatment of metastatic TNBC, mUC, HR+/HER2- breast cancer, NSCLC, SCLC, head and neck cancer, and endometrial cancer, in the currently anticipated timelines or at all; Gileads ability to receive regulatory approvals for such indications in a timely manner or at all, and the risk that any such approvals may be subject to significant limitations on use; the possibility that Gilead may make a strategic decision to discontinue development of Trodelvy for such indications and as a result, Trodelvy may never be commercialized for these indications; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gileads Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.
U.S. Prescribing Information for Trodelvy including BOXED WARNING, is available at http://www.gilead.com .
Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the companys website at http://www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
i Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer Version 4.2022. National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed August 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906006036/en/
Jacquie Ross, Investorsinvestor_relations@gilead.com
Nathan Kaiser, MediaNathan.kaiser@gilead.com
Source: Gilead Sciences, Inc.
The rest is here:
Trodelvy Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study - Gilead Sciences
- More Stem Cells Extracted For Later Use For My MS [Last Updated On: March 14th, 2011] [Originally Added On: March 14th, 2011]
- Macular Degeneration Improved With Stem Cells [Last Updated On: April 2nd, 2011] [Originally Added On: April 2nd, 2011]
- Macular Degeneration Improved With Stem Cells [Last Updated On: April 3rd, 2011] [Originally Added On: April 3rd, 2011]
- Cells That Heal Us From Cradle To Grave: A Quantum Leap in Medical Science [Last Updated On: April 6th, 2011] [Originally Added On: April 6th, 2011]
- Stem Cell Patient Richard H. MS Treatment [Last Updated On: May 20th, 2011] [Originally Added On: May 20th, 2011]
- STEM CELLS FOR MACULAR DEGENERATION Sam Smith's story.wmv [Last Updated On: May 22nd, 2011] [Originally Added On: May 22nd, 2011]
- STEM CELLS FOR MACULAR DEGENERATION Sam Smith's story.wmv [Last Updated On: May 22nd, 2011] [Originally Added On: May 22nd, 2011]
- Dr. Janet Rossant, Premier's Summit Award 2010 recipient [Last Updated On: May 31st, 2011] [Originally Added On: May 31st, 2011]
- Visions Episode 92: Stem Cells Discovery [Last Updated On: May 31st, 2011] [Originally Added On: May 31st, 2011]
- PROSTATE CANCER and stem cells.wmv [Last Updated On: June 9th, 2011] [Originally Added On: June 9th, 2011]
- Stem Cells Used to Grow Windpipes [Last Updated On: June 10th, 2011] [Originally Added On: June 10th, 2011]
- Visions Episode 92: Stem Cells Discovery [Last Updated On: July 12th, 2011] [Originally Added On: July 12th, 2011]
- PROSTATE CANCER and stem cells [Last Updated On: July 16th, 2011] [Originally Added On: July 16th, 2011]
- Doctors Use Stem Cells to Grow New Windpipes [Last Updated On: August 29th, 2011] [Originally Added On: August 29th, 2011]
- Sims 2 Mafia Story Part 7 - Farewell, Godfather/Stem Cell Medicine [Last Updated On: August 30th, 2011] [Originally Added On: August 30th, 2011]
- Regenerative Medicine: Pathways to Cure - Version 2.0 [Last Updated On: September 8th, 2011] [Originally Added On: September 8th, 2011]
- Stem Cell Research: Huntington's Disease [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Adult Stem Cell Therapy for COPD: One Man's Story [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Stem Cell Update from Panama 3 Years Later [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Stem Cell Update from Panama 3 Years Later [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- Regenerative Medicine and Applications of Stem Cell Research [Last Updated On: October 10th, 2011] [Originally Added On: October 10th, 2011]
- Stem Cell Therapy for Sickle Cell Anemia - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Stem_Cell_Therapy_for_ALS.wmv - Video [Last Updated On: October 17th, 2011] [Originally Added On: October 17th, 2011]
- Spinal Cord Injury: Progress and Promise in Stem Cell Research - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- Stem Cells: The Hope The Hype and the Science - Video [Last Updated On: October 22nd, 2011] [Originally Added On: October 22nd, 2011]
- What are stem cells? How can they be used for medical benefit? - Video [Last Updated On: October 24th, 2011] [Originally Added On: October 24th, 2011]
- What are stem cells? How can they be used for medical benefit? - Video [Last Updated On: October 25th, 2011] [Originally Added On: October 25th, 2011]
- Batten Disease: Spotlight on Stem Cell Research - Stephen Huhn - Video [Last Updated On: October 26th, 2011] [Originally Added On: October 26th, 2011]
- The CIRM Creativity Awards: Training 21st Century Stem Cell Scientists - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- What Organ Shortage? Just Make Your Own! Stem Cells and Organ Engineering - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- StemEnhance is the Biggest Scientific Medical breakthrough of our time - World Exclusive! - Video [Last Updated On: November 9th, 2011] [Originally Added On: November 9th, 2011]
- StemEnhance is the Biggest Scientific Medical breakthrough of our time - World Exclusive! - Video [Last Updated On: November 10th, 2011] [Originally Added On: November 10th, 2011]
- Alumni Profile: Dr. John Tisdale, NIH Researcher, Stem Cell Transplants and Sickle Cell - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- Intel co-founder Andrew Grove gives keynote at 2011 World Stem Cell Summit in Pasadena - Video [Last Updated On: November 16th, 2011] [Originally Added On: November 16th, 2011]
- Austin Forum - Nov 1st (Highlights) - Video [Last Updated On: November 17th, 2011] [Originally Added On: November 17th, 2011]
- Stem Cell Based Therapies for Blindness: David Hinton - CIRM Science Writer's Seminar - Video [Last Updated On: November 18th, 2011] [Originally Added On: November 18th, 2011]
- Dr. Jordan Pomeroy discusses xeno-Free Derivation and Maintenance of Pluripotent Cell Lines - Video [Last Updated On: November 19th, 2011] [Originally Added On: November 19th, 2011]
- So Many Chemicals...So Little Time: Stem Cell Research and Environmental Health - Video [Last Updated On: November 19th, 2011] [Originally Added On: November 19th, 2011]
- Austin Forum - Nov 1st (Part 4 of 4) - Video [Last Updated On: November 23rd, 2011] [Originally Added On: November 23rd, 2011]
- Austin Forum - Nov 1st (Part 2 of 4) - Video [Last Updated On: November 23rd, 2011] [Originally Added On: November 23rd, 2011]
- Austin Forum - Nov 1st (Part 1 of 4) - Video [Last Updated On: November 24th, 2011] [Originally Added On: November 24th, 2011]
- Alan Trounson: Are stem cells the end of disease? - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- Alan Trounson: Are stem cells the end of disease? - Video [Last Updated On: November 29th, 2011] [Originally Added On: November 29th, 2011]
- A4M Stem Cell Fellowship Module II Preview - Video [Last Updated On: December 1st, 2011] [Originally Added On: December 1st, 2011]
- Auxogyn_ASRM_FINAL.mov - Video [Last Updated On: December 2nd, 2011] [Originally Added On: December 2nd, 2011]
- Bruce Lipton,making the connections part 1 - Video [Last Updated On: December 3rd, 2011] [Originally Added On: December 3rd, 2011]
- Assessment of Embryo Viability (Auxogyn_ASRM_First Prize) - Video [Last Updated On: December 4th, 2011] [Originally Added On: December 4th, 2011]
- What is Cord Blood Banking? The Medical Potential of Newborn Stem Cells - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- NAMCP 2011: Ravi Vij, MD, Associate Professor of Medicine, Washington University School of Medicine - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- StemCellTV Talks to Michael Werner of Alliance for Regenerative Medicine at Meeting on the Mesa - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- Future360 - Alan Trounson, CEO of the California Institute of Regenerative Medicine - Video [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]
- 2011 World Stem Cell Summit Open Comments [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 2011 Summit: Keynote Address, CIRM's Translational Roadmap to Stem Cell Cures, Alan Trounson, PhD - Video [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- 2011 Summit: Government [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- Autism Stem Cell Trip - Video [Last Updated On: December 17th, 2011] [Originally Added On: December 17th, 2011]
- GeneCell International Dental Pulp Stem Cell's Banking Services - Video [Last Updated On: December 21st, 2011] [Originally Added On: December 21st, 2011]
- GeneCell International Dental Pulp Stem Cell's Banking Services - Video [Last Updated On: December 22nd, 2011] [Originally Added On: December 22nd, 2011]
- Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan - Video [Last Updated On: January 2nd, 2012] [Originally Added On: January 2nd, 2012]
- Craig Venter: Understanding Our Genes - A Step to Personalized Medicine | CIRM Spotlight on Genomics - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- Craig Venter: Understanding Our Genes - A Step to Personalized Medicine | CIRM Spotlight on Genomics - Video [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- Aesthetic Plastic Surgery / Anti Aging Medicine: The Next Generation Symposium Attracts a World Class Faculty to New ... [Last Updated On: January 28th, 2012] [Originally Added On: January 28th, 2012]
- Lecture by stem cell researcher tomorrow [Last Updated On: January 29th, 2012] [Originally Added On: January 29th, 2012]
- Biobanking for Medicine: Technology and Market 2012-2022 [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- 'Personalized medicine' gets $67.5M research boost [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Clinical Trial for Myelofibrosis that Targets Cancer Stem Cells | CIRM Spotlight on Genomics - Video [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use - James P. Watson, MD - Video [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use - James P. Watson, MD - Video [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- Dr. Ramaswamy on Targeting Dormant Cancer Cells - Video [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- Daniel Kraft on Singularity 1 on 1 (part 3) - Video [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- Daniel Kraft on Singularity 1 on 1 (part 1) - Video [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- Statement - Rx&D Applauds Government of Canada for Investing in Personalized Medicine [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- Molecules to Medicine: Plan B: The Tradition of Politics at the FDA [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- 'Personalized medicine' gets $67.5M research boost [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- The Pet Corner: Behold! The future of modern medicine is here [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- Molecules to Medicine: Plan B: The Tradition of Politics at the FDA [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- Treating Brain Injuries With Stem Cell Transplants - Promising Results [Last Updated On: February 4th, 2012] [Originally Added On: February 4th, 2012]
- Stem Cells to Treat Acne Scarring | Los Angeles | Hollywood | Beverly Hills - Video [Last Updated On: February 6th, 2012] [Originally Added On: February 6th, 2012]
- American CryoStem Completes Cell Processing for Clinical Study [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- IntelliCell Demonstrates at the American Sports Medicine Institute Held in Conjunction with and at the Andrews Sports ... [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- Meet the Founders of Cord Blood Registry - Video [Last Updated On: February 9th, 2012] [Originally Added On: February 9th, 2012]